Now Playing
Opinion|Videos|March 4, 2025
Treatment Options in mCRC: A Clinical Overview
Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide an overview of the third-line treatment options for mCRC for patients with disease that has progressed through all available regimens.
- Fruquintinib
- Regorafenib
- Trifluridine + tipiracil ± bevacizumab
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Unexplained Pauses Hit Nearly Half of Monthly-Updated CDC Databases, Raising Transparency Concerns
2
5 Ongoing Phase 3 Trials in Hematologic Malignancies
3
CRC Becomes Leading Cause of Cancer-Related Death in Younger Adults, Highlighting Prevention Gaps
4
ACE Inhibitors Linked to Reduced Mortality in Patients with Idiopathic Pulmonary Fibrosis
5
